<DOC>
	<DOC>NCT00612417</DOC>
	<brief_summary>Single administration of recombinant FVIII/placebo in healthy male subjects who have been treated with a single dose of anti-factor VIII antibody, TB-402</brief_summary>
	<brief_title>Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402</brief_title>
	<detailed_description />
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Inclusion Criteria include: Males 18 to 45 years of age Healthy according to medical history, physical exam, ECG, blood pressure and heart rate, and laboratory profile of blood and urine Exclusion Criteria include: Self or family history of cardiovascular or pulmonary disorder, or coagulation or bleeding disorders or reasonable suspicion of vascular malformations e.g. cerebral haemorrhage, aneurysm or premature stroke History of important bleeding episodes Previous allergic reaction to immunoglobulin Present or previous history of severe allergy, for example asthma or anaphylactic reactions FVIII:C &lt;50% or &gt;150% at screening Clinically significant out of range values for any coagulation test during screening Received prescribed medication, over the counter medication or herbal medicines within 14 days of receipt of TB402</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Interaction with recombinant FVIII</keyword>
</DOC>